Skip to main content

Table 1 Baseline characteristics of the study population

From: Modified triglyceride-glucose indices as novel predictors of metabolic dysfunction-associated fatty liver disease in US adolescents: a nationally representative study from NHANES 2017–2020

Variable

Total

(n = 532)

Non-MAFLD

(n = 402)

MAFLD

(n = 130)

p

Age (years)

14.98 (0.10)

14.87 (0.12)

15.36 (0.25)

0.064

Gender (%)

   

0.476

 Male

276 (52.0)

208 (51.1)

68 (54.9)

 

 Female

256 (48.0)

194 (48.9)

62 (45.1)

 

Race (%)

   

0.007

 Mexican American

90 (17.0)

59 (13.1)

31 (30.1)

 

 Other Hispanic

52 (8.2)

34 (7.2)

18 (11.4)

 

 Non-Hispanic White

169 (50.3)

132 (54.3)

37 (37.0)

 

 Non-Hispanic Black

119 (13.1)

95 (13.6)

24 (11.6)

 

 Other Race

102 (11.4)

82 (11.9)

20 (9.8)

 

Weight (kg)

66.26 (0.98)

59.81 (0.82)

87.91 (1.75)

 < 0.001

Height (cm)

166.03 (0.55)

165.86 (0.67)

166.59 (1.03)

0.307

BMI (kg/m2)

23.92 (0.31)

21.65 (0.29)

31.56 (0.59)

 < 0.001

Hip circumference (cm)

96.37 (0.60)

92.21 (0.64)

110.35 (1.07)

 < 0.001

Waist circumference (cm)

81.58 (0.85)

76.04 (0.58)

100.21 (1.34)

 < 0.001

Diastolic blood pressure (mmHg)

64 (0.4)

63 (0.5)

68 (0.9)

 < 0.001

Systolic blood pressure (mmHg)

109 (0.6)

108 (0.7)

110 (1.2)

0.212

AST (U/L)

19.70 (0.44)

19.20 (0.52)

21.42 (0.74)

0.009

ALT (U/L)

16.16 (0.48)

14.53 (0.53)

21.66 (1.32)

 < 0.001

Total Bilirubin (umol/L)

8.45 (0.35)

8.98 (0.43)

6.66 (0.34)

0.001

HbA1c (%)

5.25 (0.01)

5.24 (0.01)

5.30 (0.03)

0.070

Fasting glucose (mmol/L)

5.41 (0.03)

5.38 (0.03)

5.51 (0.06)

0.019

Insulin (mU/L)

12.86 (0.46)

10.21 (0.40)

21.80 (1.11)

 < 0.001

Total cholesterol (mmol/L)

3.96 (0.06)

3.93 (0.07)

4.05 (0.06)

0.082

LDL cholesterol (mmol/L)

2.25 (0.05)

2.21 (0.05)

2.38 (0.04)

0.003

Triglyceride (mmol/L)

0.78 (0.03)

0.73 (0.03)

0.98 (0.05)

 < 0.001

HDL cholesterol (mmol/L)

1.36 (0.02)

1.39 (0.02)

1.22 (0.03)

 < 0.001

CRP (mg/L)

1.98 (0.15)

1.63 (0.20)

3.17 (0.24)

 < 0.001

HOMA-IR

3.13 (0.12)

2.46 (0.10)

5.38 (0.28)

 < 0.001

WHtR

0.49 (0.01)

0.46 (0.00)

0.60 (0.01)

 < 0.001

WHR

0.84 (0.01)

0.82 (0.00)

0.91 (0.01)

 < 0.001

TyG index

8.00 (0.04)

7.94 (0.05)

8.22 (0.05)

 < 0.001

TyG-BMI

191.1 (2.84)

171.95 (2.45)

259.92 (5.25)

 < 0.001

TyG-WC

654.60 (7.99)

603.99 (5.65)

824.79 (12.14)

 < 0.001

TyG-WHtR

3.95 (0.05)

3.64 (0.04)

4.79 (0.08)

 < 0.001

TyG-WHR

6.75 (0.06)

6.54 (0.05)

7.46 (0.07)

 < 0.001

CAP (db/m)

220.75 (3.44)

198.40 (1.61)

295.91 (4.66)

0.009

Hypertension (%)

15 (3.4)

6 (2.5)

9 (6.6)

0.154

Diabetes or prediabetes (%)

57 (8.5)

31 (6.2)

26 (16.2)

0.002

Obesity (%)

126 (20.9)

34 (6.3)

92 (70.4)

 < 0.001

  1. Data are expressed as weighted means ± standard error (SE) for continuous variables and weighted proportions for categorical variables. BMI Body Mass Index; AST aspartate aminotransferase; ALT alanine aminotransferase; HbA1c Hemoglobin A1c; LDL low density lipoprotein; HDL high density lipoprotein; CRP C-reactive protein; HOMA-IR homeostatic model assessment for insulin resistance; TyG triglyceride to glucose index; WHR waist-to-hip ratio; WHtR waist-to-height ratio; CAP controlled attenuation parameter